The success of Vertex's opioid alternative Journavx could aid a group of biotechs that aim to take a similar path with NaV1.8 ...

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” first quarter 2025 ...

Vertex Pharmaceuticals encountered a challenging first quarter in 2025, as both revenue and non-GAAP profit fell short of ...

Vertex Pharmaceuticals' leap into the Russell 1000 Index marks its transformation from growth-focused biotech to blue-chip ...

When faced with the myriad diseases and equally numerous targets for potential drugs the company could pursue, Kewalramani ...

In terms of liquidity and interest, the mean open interest for Vertex Pharmaceuticals options trades today is 82.0 with a ...

A high-level overview of Vertex Pharmaceuticals Incorporated (VRTX) stock. View (VRTX) real-time stock price, chart, news, analysis, analyst reviews and more.

Vertex Pharma's non-opioid painkiller suzetrigine was unable to perform better than placebo in a phase 2 trial in lumbosacral radiculopathy (LSR), a form of neuropathic back pain, ahead of an FDA ...

By Pamela Mahler June 26, 2025. Bay Area pain management clinics can help when chronic pain, injuries or post-surgical discomfort persist. These top pain clinic doctors stay on the cutting edge of ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the best fundamental stocks to buy according to hedge funds. With a price target of $550, H.C.

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880.